J&J, Takeda recall Velcade drug batches on particle concerns
This article was originally published in Scrip
Janssen-Cilag, a unit of Johnson & Johnson, and Millennium Pharmaceuticals, a unit of Takeda, are recalling thousands of vials of the anticancer Velcade (bortezomib) sold in Europe, the US, Japan and Malaysia after receiving reports of white particulate matter – said to be polyester-like material -floating in vials of the medicine. The recall was first announced on 18 November by the UK Medicines and Healthcare Products Regulatory Agency "as a precaution" after five reports of visual particulates were received following product reconstitution in samples from two different batches, distributed between January and June of this year. Since then, the precautionary recall has been expanded to the US and Japan as well.
You may also be interested in...
ChemoCentryx has successfully completed its initial public offering on Nasdaq, raising $45 million to help support its multiple R&D programmes. It sold 4.5 million shares at $10, a somewhat less ambitious debut than it had originally planned in January when it wanted to sell four million shares at $14-$16. The reduced offer is a sign of the challenging nature of the IPO market, but ChemoCentryx's assessment of its own worth was at least closer to the market’s assessment that Cempra which got its IPO away on 6 February at valuation that was less than two-thirds of that implied by its initial prospectus (scripintelligence.com, 7 February 2012).
Ampio Pharmaceuticals, a development-stage company, initially raised $15 million which was boosted to $16.9 million by the exercise of overallotments by brokers. The shares were offered at $3.25, an 8.5% discount to the closing price of $3.66 on 12 July. The market pushed them down slightly further to 3.21 on 13 July.
Verastem, a cancer stem cells startup, has moved quickly to build its pipeline just five months after an initial public offering. Management at the Cambridge, Massachusetts firm believes that recent moves have accelerated Verastem's clinical development plans by a year.